- Stocks
- Healthcare
- NASDAQ: ATNX

Price (delayed)

$1.39

Market cap

$12.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$15.81

Enterprise value

$105.52M

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment

The EPS has soared by 59% YoY and by 50% from the previous quarter

ATNX's net income is up by 48% year-on-year and by 40% since the previous quarter

The gross profit has grown by 27% since the previous quarter but it has declined by 18% year-on-year

The gross margin has contracted by 24% YoY but it has grown by 22% from the previous quarter

ATNX's equity has dropped by 126% since the previous quarter and by 113% year-on-year

The quick ratio has contracted by 36% from the previous quarter and by 36% YoY

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.athenex.com

Peers:
OCUP

What are the main financial stats of ATNX

Market
Valuations
Earnings

Shares outstanding

8.66M

Market cap

$12.04M

Enterprise value

$105.52M

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

0.09

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.03

Revenue

$102.82M

EBIT

-$77.24M

EBITDA

-$74.92M

Free cash flow

-$75.43M

Per share
Balance sheet
Liquidity

EPS

-$15.81

Free cash flow per share

-$11.53

Book value per share

-$0.83

Revenue per share

$15.72

TBVPS

$20.17

Total assets

$204.06M

Total liabilities

$228.24M

Debt

$129.1M

Equity

-$6.51M

Working capital

$10.05M

Debt to equity

-19.84

Current ratio

1.09

Quick ratio

0.56

Net debt/EBITDA

-1.25

Margins
Efficiency
Dividend

EBITDA margin

-72.9%

Gross margin

26%

Net margin

-100.6%

Operating margin

-68.1%

Return on assets

-46.4%

Return on equity

-606%

Return on invested capital

-52.2%

Return on capital employed

-86.6%

Return on sales

-75.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Athenex stock price performed over time

Intraday

6.92%

1 week

-21.02%

1 month

-49.27%

1 year

-93.05%

YTD

-52.88%

QTD

-52.88%

How have Athenex's revenue and profit performed over time

Revenue

$102.82M

Gross profit

$26.7M

Operating income

-$70.01M

Net income

-$103.43M

Gross margin

26%

Net margin

-100.6%

The operating margin has surged by 57% year-on-year and by 46% since the previous quarter

The operating income has soared by 53% YoY and by 44% from the previous quarter

Athenex's net margin has soared by 52% YoY and by 43% from the previous quarter

ATNX's net income is up by 48% year-on-year and by 40% since the previous quarter

What is Athenex's growth rate over time

What is Athenex stock price valuation

P/E

N/A

P/B

N/A

P/S

0.09

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.03

The EPS has soared by 59% YoY and by 50% from the previous quarter

ATNX's equity has dropped by 126% since the previous quarter and by 113% year-on-year

The stock's P/S is 99% below its 5-year quarterly average of 7.0 and 82% below its last 4 quarters average of 0.5

The revenue has increased by 8% YoY and by 4% from the previous quarter

How efficient is Athenex business performance

The ROS has soared by 62% YoY and by 51% from the previous quarter

ATNX's return on invested capital is up by 42% since the previous quarter and by 28% year-on-year

ATNX's ROA is up by 36% QoQ and by 18% YoY

Athenex's return on equity has decreased by 10% QoQ

What is ATNX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ATNX.

How did Athenex financials performed over time

The total assets is 11% less than the total liabilities

The quick ratio has contracted by 36% from the previous quarter and by 36% YoY

Athenex's current ratio has decreased by 27% QoQ and by 22% YoY

ATNX's equity has dropped by 126% since the previous quarter and by 113% year-on-year

Athenex's debt has decreased by 13% YoY but it has increased by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.